The Peripheral Neuropathy (Sensory Neuropathy) drugs in development market research report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Peripheral Neuropathy (Sensory Neuropathy). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued products.
GlobalData tracks 61 drugs in development for Peripheral Neuropathy (Sensory Neuropathy) by 53 companies/universities/institutes. The top development phase for Peripheral Neuropathy (Sensory Neuropathy) is preclinical with 22 drugs in that stage. The Peripheral Neuropathy (Sensory Neuropathy) pipeline has 56 drugs in development by companies and five by universities/ institutes. Some of the companies in the Peripheral Neuropathy (Sensory Neuropathy) pipeline products market are: Johnson & Johnson, Argenx and Zai Lab.
The key targets in the Peripheral Neuropathy (Sensory Neuropathy) pipeline products market include IgG Receptor FcRn Large Subunit p51, Glucagon Like Peptide 1 Receptor, and Histone Deacetylase 6.
The key mechanisms of action in the Peripheral Neuropathy (Sensory Neuropathy) pipeline product include IgG Receptor FcRn Large Subunit p51 Antagonist with five drugs in Pre-Registration. The Peripheral Neuropathy (Sensory Neuropathy) pipeline products include nine routes of administration with the top ROA being Intravenous and 14 key molecule types in the Peripheral Neuropathy (Sensory Neuropathy) pipeline products market including Small Molecule, and Monoclonal Antibody.
Peripheral Neuropathy (Sensory Neuropathy) overview
Peripheral neuropathy refers to a condition that involves damage or dysfunction of the peripheral nerves, resulting in various sensory, motor, and autonomic symptoms. These nerves transmit signals between the central nervous system (brain and spinal cord) and the rest of the body, controlling muscle movements, sensation, and organ function. There are different types of peripheral neuropathy, each affecting specific nerves and causing varying symptoms: Sensory neuropathy, motor neuropathy, and autonomic neuropathy. Sensory neuropathy primarily affects sensory nerves, leading to sensations of tingling, numbness, burning, increased sensitivity to touch, sharp or stabbing pains, and difficulty with coordination and balance. It can affect the hands, feet, arms, or legs. Motor neuropathy affects motor nerves, resulting in muscle weakness, loss of coordination, or muscle cramps. Autonomic neuropathy involves nerves regulating involuntary bodily functions, causing symptoms like changes in blood pressure, heart rate, digestion, sweating, and bladder control. Peripheral neuropathy can have various causes. Diabetic neuropathy is one of the most common causes, affecting individuals with uncontrolled or poorly managed diabetes. Accidents, repetitive stress injuries, or trauma can damage nerves. Certain viral or bacterial infections like Lyme disease, HIV/AIDS, or shingles can lead to neuropathy. Exposure to toxins, such as heavy metals, certain medications, or chemicals, can damage nerves. Some forms of neuropathy are inherited.
For a complete picture of Peripheral Neuropathy (Sensory Neuropathy)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
